Physical Activity in Children at Risk of Post-thrombotic Sequelae (PACT) (PACT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03075761 |
Recruitment Status :
Completed
First Posted : March 9, 2017
Last Update Posted : January 7, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Post Thrombotic Syndrome Deep Vein Thrombosis | Device: Fitbit Behavioral: 30-minute education session | Not Applicable |
The feasibility of an innovative intervention of a validated fitness tracker, the Fitbit, to improve adherence to a 12-week activity regimen in a pilot randomized controlled trial (RCT) will be tested in 44 subjects with first, acute, proximal lower extremity deep vein thrombosis (DVT).
The primary outcomes will consist of a) feasibility indicators determined a priori (eligibility, consent, adherence, retention) and b) estimates of effect size associated with the prescribed activity regimen, by describing within-subject change in QoL and potential biomarkers of postthrombotic syndrome (PTS) pre and post intervention in each group.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 23 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Other |
Official Title: | Physical Activity in Children at Risk of Post-thrombotic Sequelae: A Pilot Randomized Controlled Trial |
Actual Study Start Date : | November 18, 2016 |
Actual Primary Completion Date : | October 9, 2019 |
Actual Study Completion Date : | October 10, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Intervention
Participants randomized to the intervention arm will receive a Fitbit, formal 30-minute education session on post-thrombotic syndrome (PTS) and benefits of increased physical activity. An individualized activity prescription will be provided and participants will be asked to maintain the target level of activity for 12 weeks after determining their habitual activity in the first 4 weeks.
|
Device: Fitbit
The Fitbit will be utilized in the intervention arm to improve adherence to a 12-week activity regimen.
Other Name: Activity tracker Behavioral: 30-minute education session |
Active Comparator: Control
Participants randomized to the control arm will receive a formal 30-minute education session on post-thrombotic syndrome (PTS) and the benefits of increased physical activity. Their physical activity will be self-reported in an activity log and by the Gordin activity questionnaire over the 16-week intervention period.
|
Behavioral: 30-minute education session |
- Proportion of screened patients who meet eligibility criteria [ Time Frame: Within 9 months ]Feasibility criteria met when assessed to be ≥ 30%
- Proportion of eligible patients who provide consent [ Time Frame: Within 9 months ]Feasibility criteria met when assessed to be ≥ 30%
- Level of adherence in the FitBit arm [ Time Frame: Within 6 months of randomization ]Feasibility criteria met when assessed to be ≥ 60%
- Proportion of subjects who complete the trial post randomization [ Time Frame: Within 6 months of randomization ]Feasibility criteria met when assessed to be ≥ 80%
- Change in PTS biomarkers pre and post intervention of increased physical activity as measured by markers of coagulation activation, inflammation and fibrinolysis [ Time Frame: Within 6 months of randomization ]Markers of coagulation activation as assessed by D-dimer, FVIII; inflammation as assessed by C-reactive protein and markers of fibrinolysis as assessed by PAI-1, in addition to global coagulation assays, namely thrombin generation and TEG-fibrinolysis
- Change in Quality of Life [ Time Frame: Within 6 months of randomization ]As assessed by PedsQL instrument
- Change in physical activity scores [ Time Frame: Within 6 months of randomization ]As determined by Gordon Questionnaire
- Elastic Compression Stocking (ECS) use assessed by ECS logs [ Time Frame: Within 6 months of randomization ]ECS use will be assessed by ECS log/diary documenting dedicated (use for at least 6 days/week), moderate (use for 4-5 days/week) or poor use (<4 days/week)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 7 Years to 21 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- A radiologically confirmed, acute, proximal first lower extremity DVT
- 4 to 8 weeks after starting anticoagulation
- Out-patient ambulatory status
Exclusion Criteria:
- Contraindication to increasing activity such as patients with juvenile arthritis, poor balance, congestive heart failure, etc.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03075761
United States, Texas | |
Children's Medical Center | |
Dallas, Texas, United States, 75235 |
Principal Investigator: | Ayesha Zia, M.D | University of Texas Southwestern Medical Center |
Responsible Party: | Ayesha Zia, Assistant Professor of Pediatrics, University of Texas Southwestern Medical Center |
ClinicalTrials.gov Identifier: | NCT03075761 |
Other Study ID Numbers: |
STU 022016-057 1K23HL132054-01 ( U.S. NIH Grant/Contract ) |
First Posted: | March 9, 2017 Key Record Dates |
Last Update Posted: | January 7, 2020 |
Last Verified: | January 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Venous thromboembolism Deep Vein Thrombosis Lower Extremity Blood clot Anticoagulation |
Physical Activity Fitbit Post-thrombotic syndrome Post-phlebitic syndrome Thrombosis |
Thrombosis Venous Thrombosis Postthrombotic Syndrome Postphlebitic Syndrome Syndrome Disease Pathologic Processes |
Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Venous Insufficiency Phlebitis Peripheral Vascular Diseases |